Can postmenopausal hormone replacement improve plasma lipids in women with diabetes?

Jennifer G. Robinson, Aaron R. Folsom, Azmi A. Nabulsi, Robert Watson, Frederick L. Brancati, Jianwen Cai

Research output: Contribution to journalArticle

Abstract

OBJECTIVE - To evaluate the association of postmenopausal hormone replacement with plasma lipids in diabetic women. RESEARCH DESIGN AND METHODS - Cross- sectional data from a multiracial population study were used to evaluate the relationship of hormone replacement status with plasma lipids in diabetic (n = 694) versus nondiabetic (n = 5,321) postmenopausal women. RESULTS - Although diabetic women who currently used hormone replacement had higher adjusted mean HDL cholesterol levels than those who did not (56.9 vs. 53.6 mg/dl), they had proportionately lower hormone-related increases in HDL, HDL, and HDL, cholesterol than did nondiabetic women (HDL cholesterol 64.9 [current users] vs. 55.7 mg/dl [those who never used hormones]). There was a trend toward greater triglyceride values with hormones replacement in diabetic women (156.6 [current users] vs. 125.4 mg/dl [those who never used hormones]) than in nondiabetic women (143.3 [current users] vs. 123.7 mg/dl [those who never used hormones]), LDL cholesterol and apolipoprotein B levels were lower and apolipoprotein A-1 levels were higher with hormone replacement to a similar degree in diabetic and nondiabetic women. CONCLUSIONS - Diabetic women appear to have a blunted response to the HDL-raising effects of estrogen and an exaggerated hypertriglyceridemic response. This may results in attenuated cardioprotection from postmenopausal hormone replacement therapy and potentially an increased risk of acute pancreatitis from hypertriglyceridemia. The risks and benefits of postmenopausal hormone replacement need to be carefully weighed in diabetic women.

Original languageEnglish (US)
Pages (from-to)480-485
Number of pages6
JournalDiabetes Care
Volume19
Issue number5
StatePublished - May 1996

Fingerprint

Hormones
Lipids
HDL Cholesterol
Estrogen Replacement Therapy
Hypertriglyceridemia
Apolipoprotein A-I
Apolipoproteins B
Pancreatitis
LDL Cholesterol
Estrogens
Triglycerides
Research Design
Population

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Robinson, J. G., Folsom, A. R., Nabulsi, A. A., Watson, R., Brancati, F. L., & Cai, J. (1996). Can postmenopausal hormone replacement improve plasma lipids in women with diabetes? Diabetes Care, 19(5), 480-485.

Can postmenopausal hormone replacement improve plasma lipids in women with diabetes? / Robinson, Jennifer G.; Folsom, Aaron R.; Nabulsi, Azmi A.; Watson, Robert; Brancati, Frederick L.; Cai, Jianwen.

In: Diabetes Care, Vol. 19, No. 5, 05.1996, p. 480-485.

Research output: Contribution to journalArticle

Robinson, JG, Folsom, AR, Nabulsi, AA, Watson, R, Brancati, FL & Cai, J 1996, 'Can postmenopausal hormone replacement improve plasma lipids in women with diabetes?', Diabetes Care, vol. 19, no. 5, pp. 480-485.
Robinson JG, Folsom AR, Nabulsi AA, Watson R, Brancati FL, Cai J. Can postmenopausal hormone replacement improve plasma lipids in women with diabetes? Diabetes Care. 1996 May;19(5):480-485.
Robinson, Jennifer G. ; Folsom, Aaron R. ; Nabulsi, Azmi A. ; Watson, Robert ; Brancati, Frederick L. ; Cai, Jianwen. / Can postmenopausal hormone replacement improve plasma lipids in women with diabetes?. In: Diabetes Care. 1996 ; Vol. 19, No. 5. pp. 480-485.
@article{4cd0ab7b41cc473d94ffd33a901b8e7e,
title = "Can postmenopausal hormone replacement improve plasma lipids in women with diabetes?",
abstract = "OBJECTIVE - To evaluate the association of postmenopausal hormone replacement with plasma lipids in diabetic women. RESEARCH DESIGN AND METHODS - Cross- sectional data from a multiracial population study were used to evaluate the relationship of hormone replacement status with plasma lipids in diabetic (n = 694) versus nondiabetic (n = 5,321) postmenopausal women. RESULTS - Although diabetic women who currently used hormone replacement had higher adjusted mean HDL cholesterol levels than those who did not (56.9 vs. 53.6 mg/dl), they had proportionately lower hormone-related increases in HDL, HDL, and HDL, cholesterol than did nondiabetic women (HDL cholesterol 64.9 [current users] vs. 55.7 mg/dl [those who never used hormones]). There was a trend toward greater triglyceride values with hormones replacement in diabetic women (156.6 [current users] vs. 125.4 mg/dl [those who never used hormones]) than in nondiabetic women (143.3 [current users] vs. 123.7 mg/dl [those who never used hormones]), LDL cholesterol and apolipoprotein B levels were lower and apolipoprotein A-1 levels were higher with hormone replacement to a similar degree in diabetic and nondiabetic women. CONCLUSIONS - Diabetic women appear to have a blunted response to the HDL-raising effects of estrogen and an exaggerated hypertriglyceridemic response. This may results in attenuated cardioprotection from postmenopausal hormone replacement therapy and potentially an increased risk of acute pancreatitis from hypertriglyceridemia. The risks and benefits of postmenopausal hormone replacement need to be carefully weighed in diabetic women.",
author = "Robinson, {Jennifer G.} and Folsom, {Aaron R.} and Nabulsi, {Azmi A.} and Robert Watson and Brancati, {Frederick L.} and Jianwen Cai",
year = "1996",
month = "5",
language = "English (US)",
volume = "19",
pages = "480--485",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "5",

}

TY - JOUR

T1 - Can postmenopausal hormone replacement improve plasma lipids in women with diabetes?

AU - Robinson, Jennifer G.

AU - Folsom, Aaron R.

AU - Nabulsi, Azmi A.

AU - Watson, Robert

AU - Brancati, Frederick L.

AU - Cai, Jianwen

PY - 1996/5

Y1 - 1996/5

N2 - OBJECTIVE - To evaluate the association of postmenopausal hormone replacement with plasma lipids in diabetic women. RESEARCH DESIGN AND METHODS - Cross- sectional data from a multiracial population study were used to evaluate the relationship of hormone replacement status with plasma lipids in diabetic (n = 694) versus nondiabetic (n = 5,321) postmenopausal women. RESULTS - Although diabetic women who currently used hormone replacement had higher adjusted mean HDL cholesterol levels than those who did not (56.9 vs. 53.6 mg/dl), they had proportionately lower hormone-related increases in HDL, HDL, and HDL, cholesterol than did nondiabetic women (HDL cholesterol 64.9 [current users] vs. 55.7 mg/dl [those who never used hormones]). There was a trend toward greater triglyceride values with hormones replacement in diabetic women (156.6 [current users] vs. 125.4 mg/dl [those who never used hormones]) than in nondiabetic women (143.3 [current users] vs. 123.7 mg/dl [those who never used hormones]), LDL cholesterol and apolipoprotein B levels were lower and apolipoprotein A-1 levels were higher with hormone replacement to a similar degree in diabetic and nondiabetic women. CONCLUSIONS - Diabetic women appear to have a blunted response to the HDL-raising effects of estrogen and an exaggerated hypertriglyceridemic response. This may results in attenuated cardioprotection from postmenopausal hormone replacement therapy and potentially an increased risk of acute pancreatitis from hypertriglyceridemia. The risks and benefits of postmenopausal hormone replacement need to be carefully weighed in diabetic women.

AB - OBJECTIVE - To evaluate the association of postmenopausal hormone replacement with plasma lipids in diabetic women. RESEARCH DESIGN AND METHODS - Cross- sectional data from a multiracial population study were used to evaluate the relationship of hormone replacement status with plasma lipids in diabetic (n = 694) versus nondiabetic (n = 5,321) postmenopausal women. RESULTS - Although diabetic women who currently used hormone replacement had higher adjusted mean HDL cholesterol levels than those who did not (56.9 vs. 53.6 mg/dl), they had proportionately lower hormone-related increases in HDL, HDL, and HDL, cholesterol than did nondiabetic women (HDL cholesterol 64.9 [current users] vs. 55.7 mg/dl [those who never used hormones]). There was a trend toward greater triglyceride values with hormones replacement in diabetic women (156.6 [current users] vs. 125.4 mg/dl [those who never used hormones]) than in nondiabetic women (143.3 [current users] vs. 123.7 mg/dl [those who never used hormones]), LDL cholesterol and apolipoprotein B levels were lower and apolipoprotein A-1 levels were higher with hormone replacement to a similar degree in diabetic and nondiabetic women. CONCLUSIONS - Diabetic women appear to have a blunted response to the HDL-raising effects of estrogen and an exaggerated hypertriglyceridemic response. This may results in attenuated cardioprotection from postmenopausal hormone replacement therapy and potentially an increased risk of acute pancreatitis from hypertriglyceridemia. The risks and benefits of postmenopausal hormone replacement need to be carefully weighed in diabetic women.

UR - http://www.scopus.com/inward/record.url?scp=0029976295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029976295&partnerID=8YFLogxK

M3 - Article

C2 - 8732713

AN - SCOPUS:0029976295

VL - 19

SP - 480

EP - 485

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 5

ER -